Drug resistance associated with antiangiogenesis therapy

Seminars in Cancer Biology

Volumn 19, Issue 5, 2009, Pages 310-317

  Eikesdal, Hans Petter ^a   Kalluri, Raghu ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Cancer; Drug resistance mechanisms

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; BCR ABL PROTEIN; BEVACIZUMAB; CANSTATIN; COMBRETASTATIN; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; ENDOSTATIN; EPHRIN A1; EPHRIN A2; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; PROLACTIN; RETINA S ANTIGEN; SUNITINIB; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; THROMBOSPONDIN 1; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VD 6126; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG UTILIZATION; ENDOTHELIUM CELL; EVIDENCE BASED PRACTICE; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MUSCULOSKELETAL DISEASE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; PATIENT COMPLIANCE; REVIEW; SIGNAL TRANSDUCTION; THEORY; TREATMENT DURATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 70549102293     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.05.006     Document Type: Review

References (138)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175 3 (1972) 409-416
3. Spalding B.J. Thumbs up for Avastin. Nat Biotechnol 26 4 (2008) 365
4. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 26 (2007) 2666-2676
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 24 (2006) 2542-2550
6. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
7. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 2 (2007) 125-134
8. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
9. Wadman M. Cancer 'cure' article stirs up hot debate. Nature 393 May 14 (1998) 104-105
10. Marshall E. The power of the front page of The New York Times. Science 280 May 15 (1998) 996-997
11. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays 13 1 (1991) 31-36
12. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 January 24 (1997) 277-285
13. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2 6 (1996) 689-692
14. Fernando N.T., Koch M., Rothrock C., Gollogly L.K., D'Amore P.A., Ryeom S., et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14 5 (2008) 1529-1539
15. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 8 (2000) R15-24
16. Eikesdal H.P., Bjorkhaug S.T., and Dahl O. Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma-lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia 18 2 (2002) 141-152
17. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., and Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67 21 (2007) 10123-10128
18. Niclou S.P., Danzeisen C., Eikesdal H.P., Wiig H., Brons N.H., Poli A.M., et al. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J 22 9 (2008) 3120-3128
19. Folkman J., Hahnfeldt P., and Hlatky L. Cancer: looking outside the genome. Nat Rev Mol Cell Biol 1 1 (2000) 76-79
20. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science 289 5482 (2000) 1197-1202
21. Boehm T., Folkman J., Browder T., and O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 6658 (1997) 404-407
22. Brem H., Goto F., Budson A., Saunders L., and Folkman J. Minimal drug resistance after prolonged antiangiogenic therapy with AGM-1470. Surg Forum XLV (1994) 674-677
23. Hida K., Hida Y., Amin D.N., Flint A.F., Panigrahy D., Morton C.C., et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64 22 (2004) 8249-8255
24. Hida K., and Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65 7 (2005) 2507-2510
25. Streubel B., Chott A., Huber D., Exner M., Jager U., Wagner O., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351 3 (2004) 250-259
26. Gunsilius E., Duba H.C., Petzer A.L., Kahler C.M., Grunewald K., Stockhammer G., et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355 9216 (2000) 1688-1691
27. Dudley A.C., Khan Z.A., Shih S.C., Kang S.Y., Zwaans B.M., Bischoff J., et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 14 3 (2008) 201-211
28. Bussolati B., Deambrosis I., Russo S., Deregibus M.C., and Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17 9 (2003) 1159-1161
29. Faivre S., Djelloul S., and Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 33 4 (2006) 407-420
30. Pham N.A., Schwock J., Iakovlev V., Pond G., Hedley D.W., and Tsao M.S. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer 8 Feb 6 (2008) 43
31. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 5 (1997) 963-969
32. Irish J.M., Hovland R., Krutzik P.O., Perez O.D., Bruserud O., Gjertsen B.T., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118 2 (2004) 217-228
33. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 4 (2005) 299-309
34. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 8 (2008) 592-603
35. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., et al. AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 1 (2007) 83-95
36. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 5848 (2007) 287-290
37. Miller K.D., Sweeney C.J., and Sledge G.W.J. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 14 1 (2003) 20-28
38. Seaman S., Stevens J., Yang M.Y., Logsdon D., Graff-Cherry C., and St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11 6 (2007) 539-554
39. Amin D.N., Bielenberg D.R., Lifshits E., Heymach J.V., and Klagsbrun M. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvasc Res 76 1 (2008) 15-22
40. Alitalo K., Tammela T., and Petrova T.V. Lymphangiogenesis in development and human disease. Nature 438 7070 (2005) 946-953
41. Zwaans B.M., and Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 74 2-3 (2007) 145-158
42. Alfranca A., Lopez-Oliva J.M., Genis L., Lopez-Maderuelo D., Mirones I., Salvado D., et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 112 4 (2008) 1120-1128
43. Scappaticci F.A., Smith R., Pathak A., Schloss D., Lum B., Cao Y., et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 3 2 (2001) 186-196
44. Eikesdal H.P., Sugimoto H., Birrane G., Maeshima Y., Cooke V.G., Kieran M., et al. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor therapy. Proc Natl Acad Sci USA 105 39 (2008) 15040-15045
45. Glade Bender J., Cooney E.M., Kandel J.J., and Yamashiro D.J. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Update 7 4-5 (2004) 289-300
46. Huang J., Soffer S.Z., Kim E.S., McCrudden K.W., Huang J., New T., et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2 1 (2004) 36-42
47. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 5 (2000) 1388-1393
48. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18 2 (2004) 338-340
49. Yonenaga Y., Mori A., Onodera H., Yasuda S., Oe H., Fujimoto A., et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 69 2 (2005) 159-166
50. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 3 (2009) 220-231
51. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 3 (2009) 232-239
52. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 10 (2002) 727-739
53. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61 13 (2001) 5090-5101
54. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 7 (2000) 1878-1886
55. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., and Smulson M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58 20 (1998) 4510-4514
56. Eikesdal H.P., Bjerkvig R., Mella O., and Dahl O. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiother Oncol 60 2 (2001) 147-154
57. Abdollahi A., Lipson K.E., Sckell A., Zieher H., Klenke F., Poerschke D., et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63 24 (2003) 8890-8898
58. Tabruyn S.P., and Griffioen A.W. Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 355 1 (2007) 1-5
59. Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., and Holmgren L. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152 6 (2001) 1247-1254
60. Wahl M.L., Kenan D.J., Gonzalez-Gronow M., and Pizzo S.V. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 96 2 (2005) 242-261
61. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60 9 (2000) 2520-2526
62. Sudhakar A., Nyberg P., Keshamouni V.G., Mannam A.P., Li J., Sugimoto H., et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115 10 (2005) 2801-2810
63. Magnon C., Galaup A., Mullan B., Rouffiac V., Bouquet C., Bidart J.M., et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 65 10 (2005) 4353-4361
64. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275 2 (2000) 1209-1215
65. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., and Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278 6 (2003) 4238-4249
66. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166 1 (2004) 97-109
67. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 274 17 (1999) 11721-11726
68. Wickstrom S.A., Alitalo K., and Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62 19 (2002) 5580-5589
69. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., et al. Endostatin's antiangiogenic signaling network. Mol Cell 13 5 (2004) 649-663
70. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., and Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 100 8 (2003) 4766-4771
71. Mundel T.M., Yliniemi A.M., Maeshima Y., Sugimoto H., Kieran M., and Kalluri R. Type IV collagen alpha6 chain-derived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer 122 8 (2008) 1738-1744
72. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6 1 (2002) 1-12
73. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 5552 (2002) 140-143
74. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
75. Sledge G.W.J., and Miller K.D. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 26 1 (2002) 1-60
76. Li C.Y., Shan S., Huang Q., Braun R.D., Lanzen J., Hu K., et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 2 (2000) 143-147
77. Sakariassen P.O., Prestegarden L., Wang J., Skaftnesmo K.O., Mahesparan R., Molthoff C., et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103 44 (2006) 16466-16471
78. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 5559 (2002) 1526-1528
79. Rubenstein J.L., Kim J., Ozawa T., Zhang M., Westphal M., Deen D.F., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 4 (2000) 306-314
80. Kunkel P., Ulbricht U., Bohlen P., Brockmann M.A., Fillbrandt R., Stavrou D., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61 18 (2001) 6624-6628
81. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 3 (2008) 206-220
82. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 5422 (1999) 1994-1998
83. Offersen B.V., Pfeiffer P., Hamilton-Dutoit S., and Overgaard J. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 91 8 (2001) 1500-1509
84. Passalidou E., Trivella M., Singh N., Ferguson M., Hu J., Cesario A., et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 86 2 (2002) 244-249
85. Hillen F., and Griffioen A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26 3-4 (2007) 489-502
86. Straume O., Chappuis P.O., Salvesen H.B., Halvorsen O.J., Haukaas S.A., Goffin J.R., et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62 23 (2002) 6808-6811
87. McDonald D.M., Munn L., and Jain R.K. Vasculogenic mimicry: how convincing, how novel, and how significant?. Am J Pathol 156 2 (2000) 383-388
88. Hendrix M.J., Seftor E.A., Hess A.R., and Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3 6 (2003) 411-421
89. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 6801 (2000) 249-257
90. Konerding M.A., Steinberg F., and Budach V. The vascular system of xenotransplanted tumors-scanning electron and light microscopic studies. Scan Microsc 3 1 (1989) 327-335 [discussion 35-6]
91. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155 3 (1999) 739-752
92. Shirakawa K., Kobayashi H., Heike Y., Kawamoto S., Brechbiel M.W., Kasumi F., et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 62 2 (2002) 560-566
93. Hendrix M.J., Seftor R.E., Seftor E.A., Gruman L.M., Lee L.M., Nickoloff B.J., et al. Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res 62 3 (2002) 665-668
94. Chang Y.S., di Tomaso E., McDonald D.M., Jones R., Jain R.K., and Munn L.L. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97 26 (2000) 14608-14613
95. Nyberg P., Salo T., and Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci 13 (2008) 6537-6553
96. Rohan R.M., Fernandez A., Udagawa T., Yuan J., and D'Amato R.J. Genetic heterogeneity of angiogenesis in mice. FASEB J 14 7 (2000) 871-876
97. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 1 (2005) 101-111
98. Kim E., Moore J., Huang J., Soffer S., Manley C.A., O'Toole K., et al. All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg 36 2 (2001) 287-290
99. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103 2 (1999) 159-165
100. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
101. Glade-Bender J., Kandel J.J., and Yamashiro D.J. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3 2 (2003) 263-276
102. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 9605 (2007) 2103-2111
103. Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 10 18 Pt 2 (2004) 6367S-6370S
104. Fukumura D., Xavier R., Sugiura T., Chen Y., Park E.C., Lu N., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94 6 (1998) 715-725
105. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 3 (2005) 335-348
106. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 2 (2006) 263-266
107. Nozawa H., Chiu C., and Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103 33 (2006) 12493-12498
108. Davis D.W., Shen Y., Mullani N.A., Wen S., Herbst R.S., O'Reilly M., et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10 1 Pt 1 (2004) 33-42
109. Motegi K., Harada K., Pazouki S., Baillie R., and Schor A.M. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 34 8-9 (2002) 411-421
110. Benelli R., Morini M., Brigati C., Noonan D.M., and Albini A. Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. Int J Oncol 22 1 (2003) 87-91
111. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65 23 (2005) 11044-11050
112. Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165 1 (2004) 35-52
113. Folkman J., and Kalluri R. Cancer without disease. Nature 427 6977 (2004) 787
114. Horsman M.R., and Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66 24 (2006) 11520-11539
115. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10 2 (2004) 415-427
116. Eikesdal H.P., Bjerkvig R., and Dahl O. Vinblastine and hyperthermia target the neovasculature in BT4An rat gliomas: therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 51 2 (2001) 535-544
117. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 15 (2003) 2831-2842
118. Landuyt W., Ahmed B., Nuyts S., Theys J., Op de Beeck M., Rijnders A., et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49 2 (2001) 443-450
119. Siemann D.W., and Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60 4 (2004) 1233-1240
120. Hinnen P., and Eskens F.A. Vascular disrupting agents in clinical development. Br J Cancer 96 8 (2007) 1159-1165
121. Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87 4 (1995) 293-298
122. Chung A.S., Yoon S.O., Park S.J., and Yun C.H. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36 1 (2003) 128-137
123. Yip D., Ahmad A., Karapetis C.S., Hawkins C.A., and Harper P.G. Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs 17 4 (1999) 387-399
124. Talbot D.C., and Brown P.D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A 14 (1996) 2528-2533
125. Pavlaki M., and Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 22 2-3 (2003) 177-203
126. Raza S.L., and Cornelius L.A. Matrix metalloproteinases: pro- and anti-angiogenic activities. J Investig Dermatol Symp Proc 5 1 (2000) 47-54
127. Cristofanilli M., Charnsangavej C., and Hortobagyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1 6 (2002) 415-426
128. Deplanque G., and Harris A.L. Anti-angiogenic agents. Clinical trial design and therapies in development. Eur J Cancer 36 13 Spec No (2000) 1713-1724
129. Low J.A., Johnson M.D., Bone E.A., and Dickson R.B. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 2 7 (1996) 1207-1214
130. Brown P.D. Clinical studies with matrix metalloproteinase inhibitors. APMIS 107 1 (1999) 174-180
131. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3 6 (2003) 589-601
132. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., and Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 97 5 (2000) 2202-2207
133. Holst-Hansen C., Low J.A., Stephens R.W., Johnson M.D., Carmeliet P., Frandsen T.L., et al. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. Breast Cancer Res Treat 68 3 (2001) 225-237
134. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 19 (2005) 2012-2024
135. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., and Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104 43 (2007) 17069-17074
136. Jubb A.M., Oates A.J., Holden S., and Koeppen H. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6 8 (2006) 626-635
137. Benson III A.B. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 13 22 Pt 2 (2007) 6913s-6920s
138. Hayes D.F., Miller K., and Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 16 Suppl. 2 (2007) S17-S19